Optimization and Plateau Considerations (Weeks 12-16+): After 12-16 weeks of use, the rate of body composition change may slow as users approach their genetic set points or as the body adapts metabolically
These products are sold strictly for research and laboratory use only , not for direct human or animal application
A proper evaluation helps ensure safety and suitability
The proposed mechanisms range from well-validated (FDA-approved GLP-1 agonists for weight loss) to highly speculative (epitalon, thymosin alpha-1, MOTS-c) with limited or no human clinical validation
Cox HD, Lopes F, Woldemariam GA, Becker JO, Parkin MC, Thomas A, Butch AW, Cowan DA, Thevis M, Bowers LD, Hoofnagle AN
For musculoskeletal use, it is commonly considered for tendon irritation, ligament sprains, muscle strains, fascia-related pain, overuse injuries, and joint-adjacent soft-tissue pain